VEEV241220P90000
- 0.34
- 0.000.00%
Veeva Systems Newsroom
Morgan Stanley Maintains Veeva Systems(VEEV.US) With Sell Rating, Maintains Target Price $183
Customer attrition has led to a decline in Veeva (VEEV.US) stock prices. Baird reassures the market: the financial impact is manageable and maintains a "Shareholding" rating.
Truist Financial Keeps Their Hold Rating on Veeva Systems (VEEV)
Truist Financial Maintains Veeva Systems(VEEV.US) With Hold Rating, Maintains Target Price $261
Veeva Systems Analyst Ratings
Veeva Systems Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Veeva Systems(VEEV.US) With Buy Rating, Announces Target Price $280
Citi Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $307
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $183 to $300
Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $275
Evercore ISI Group Maintains In-Line on Veeva Systems, Raises Price Target to $245
KeyBanc Raises Veeva Systems Price Target to $285 From $240, Maintains Overweight Rating
Veeva Systems Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $285
Wells Fargo Maintains Overweight on Veeva Systems, Raises Price Target to $285
UBS Raises Price Target on Veeva Systems to $250 From $245, Keeps Neutral Rating
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Novavax (NVAX) and Veeva Systems (VEEV)
Baird Maintains Outperform on Veeva Systems, Raises Price Target to $283
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $183 to $290
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)